Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA "Re-Repositioning"? Working Group Studying Rx Affordability Ahead Of Annual Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer exec Katen is overseeing group studying access and affordability issues. Association hopes to build on spirit of "repositioning" work that led to marketing guidelines in 2002.

You may also be interested in...



PhRMA Taps Former Hill Staffer Easton To Head Affordability, Access Group

Michelle Easton will oversee advocacy efforts on a wide range of programs and will work closely with health care partners in the newly created role of VP-group on affordability & access. She was a legislative assistant for former Rep. (now PhRMA CEO) Tauzin before working in former Sen. Breaux’s office for eight years.

Is The Opioid REMS Too Big To Study?

US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.

Topics

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel